Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Frankfurt - Delayed Quote EUR

Lipigon Pharmaceuticals AB (publ) (9RP.F)

Compare
0.0107
-0.0005
(-4.46%)
At close: March 14 at 8:46:54 AM GMT+1
Loading Chart for 9RP.F
  • Previous Close 0.0112
  • Open 0.0107
  • Bid 0.0009 x --
  • Ask 0.0308 x --
  • Day's Range 0.0107 - 0.0107
  • 52 Week Range 0.0001 - 0.0276
  • Volume 109
  • Avg. Volume 2,035
  • Market Cap (intraday) 2.348M
  • Beta (5Y Monthly) 0.86
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0200
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease; a gene therapy project for the treatment of the rare disease lipodystrophy; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia. The company was incorporated in 2010 and is based in Umeå, Sweden.

www.lipigon.se

6

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 9RP.F

View More

Performance Overview: 9RP.F

Trailing total returns as of 3/14/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index .

YTD Return

9RP.F
970.00%
OMX Stockholm 30 Index
8.02%

1-Year Return

9RP.F
36.31%
OMX Stockholm 30 Index
6.11%

3-Year Return

9RP.F
97.60%
OMX Stockholm 30 Index
27.95%

5-Year Return

9RP.F
98.84%
OMX Stockholm 30 Index
94.87%

Compare To: 9RP.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 9RP.F

View More

Valuation Measures

As of 3/14/2025
  • Market Cap

    2.34M

  • Enterprise Value

    1.37M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.42

  • Price/Book (mrq)

    0.95

  • Enterprise Value/Revenue

    1.70

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -246.49%

  • Return on Assets (ttm)

    -59.89%

  • Return on Equity (ttm)

    -107.35%

  • Revenue (ttm)

    8.97M

  • Net Income Avi to Common (ttm)

    -22.11M

  • Diluted EPS (ttm)

    -0.0200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    10.74M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -24.61M

Research Analysis: 9RP.F

View More